|
Capoxigem: Bibliography
Kastrissios, H. et al. Development of a Predictive Pharmacokinetic Model for a Novel Cyclooxygenase-2 Inhibitor. Journal of Clinical Pharmacology 46, 537-548 (2006).
Kiguchi, K. et al. Therapeutic Effect of CS-706, a Specific Cyclooxygenase-2 Inhibitor, on Gallbladder Carcinoma in BK5.ErB-2 Mice. Molecular Cancer Therapeutics 6, 1709-1717 (2007).
Moberly, J. et al. A Randomized, Double-Blind, One-Week Study Comparing Effects of a Novel COX-2 Inhibitor and Naproxen on the Gastric Mucosa. Digestive Diseases and Sciences 52, 442-450 (2007).
Moberly, J. et al. A Randomized, Double-Blind, Celecoxib-and Placebo-Controlled Study of the Effectiveness of CS-706 in Acute Postoperative Dental Pain. Clinical Therapeutics 29, 399-412 (2007).
Oitate, M. Covalent Binding of Radioactivity from [14C] Rofecoxib, but not [14C] Celecoxib or [14C] CS-706, to the Arterial Elastic of Rats. Drug Metabolism and Disposition 34, 1417-1422 (2006).
Reckamp, K. et al. Biomarker Based Phase I Dose-Escalation, Pharmacokinetic
and Pharmacodynamic Study of Oral Apricoxib in Combination
with Erlotinib in Advanced Non-Small Cell Lung Cancer. Cancer,
In Press (2010).
Rohatagi, S. et al. Predictive Population Pharmacokinetic/Pharmacodynamic
Model for a Novel COX-2 Inhibitor. Journal of Clinical Pharmacology
47, 1-13 (2007).
Senzaki, M. et al. CS-706, A Novel Cyclooxygenase-2 Selective Inhibitor, Prolonged the Survival of Tumor-Bearing Mice When Treated Alone or in Combination with Anti-Tumor Chemotherapeutic Agents. International Journal of Cancer 122, 1384-1390 (2007).
Ushiyama, S. et al. Preclinical Pharmacology Profile of CS-706, a Novel Cyclooxygenase-2 Selective Inhibitor, with Potent Antinociceptive and Anti-Inflammatory Effects. European Journal of Pharmacology 578, 76-86 (2007).
| 
